| scholarly article | Q13442814 |
| P356 | DOI | 10.1124/JPET.114.222463 |
| P698 | PubMed publication ID | 25665805 |
| P50 | author | Thomas Kilduff | Q16730839 |
| Markus von Kienlin | Q46055601 | ||
| Stephen R Morairty | Q125318870 | ||
| Joseph G Wettstein | Q125318926 | ||
| P2093 | author name string | Lothar Lindemann | |
| Edilio Borroni | |||
| Will Spooren | |||
| Jean-Luc Moreau | |||
| Thomas Hartung | |||
| Michael Honer | |||
| Manfred Schneider | |||
| Christoph Funk | |||
| Neil J Parrott | |||
| Axel Paehler | |||
| Sebastian H Scharf | |||
| Georg Jaeschke | |||
| Sabine Kolczewski | |||
| Eric Vieira | |||
| Andreas Bruns | |||
| Basil Kuennecke | |||
| Liudmila Polonchuk | |||
| Eric Prinssen | |||
| Juergen Wichmann | |||
| Urs Niederhauser | |||
| Andreas Gloge | |||
| Anthony C Harrison | |||
| Richard H Porter | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 213-233 | |
| P577 | publication date | 2015-02-09 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression | |
| P478 | volume | 353 |
| Q52367722 | Advances in Drug Discovery and Development in Geriatric Psychiatry. |
| Q48077200 | Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. |
| Q34557706 | Beyond serotonin: newer antidepressants in the future |
| Q50119965 | Bidirectional variation in glutamate efflux in the medial prefrontal cortex induced by selective positive and negative allosteric mGluR5 modulators. |
| Q40335459 | Computer-aided design of negative allosteric modulators of metabotropic glutamate receptor 5 (mGluR5): Comparative molecular field analysis of aryl ether derivatives |
| Q93181944 | Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5 |
| Q48116127 | Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation |
| Q45957740 | Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. |
| Q38620643 | Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results. |
| Q90194187 | Enhanced Function and Overexpression of Metabotropic Glutamate Receptors 1 and 5 in the Spinal Cord of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis during Disease Progression |
| Q38895017 | Glutamate-Based Drug Discovery for Novel Antidepressants |
| Q57472015 | Hippocampal deficits in neurodevelopmental disorders |
| Q34547274 | Investigational drugs for treating major depressive disorder |
| Q48036786 | Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized. |
| Q52600080 | Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy. |
| Q57817547 | Metabotropic Glutamate Receptor 5 in the Medial Prefrontal Cortex as a Molecular Determinant of Pain and Ensuing Depression |
| Q38690069 | Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging |
| Q38567309 | Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias |
| Q37741989 | Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13). |
| Q91613577 | Molecular Biomarkers in Fragile X Syndrome |
| Q39955646 | N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents |
| Q26775243 | Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic Window |
| Q38685420 | New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity. |
| Q30709836 | Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects |
| Q64928871 | Population Pharmacokinetic and Exposure-dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients. |
| Q96155925 | Targeting of Metabotropic Glutamate Receptors for the Development of Novel Antidepressants |
| Q37172873 | The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders |
| Q64071039 | The Role of Metabotropic Glutamate Receptors in Social Behavior in Rodents |
| Q47382890 | The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders |
| Q37668029 | Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants |
| Q38603032 | Upregulation of prefrontal metabotropic glutamate receptor 5 mediates neuropathic pain and negative mood symptoms after spinal nerve injury in rats. |
| Q39076410 | mGlu5 negative allosteric modulators: a patent review (2013 - 2016). |
Search more.